SPECIFICA, INC.
Biotech · Acquired
Therapeutic antibodies and antibody libraries selected via phage display, yeast display, and next-generation sequencing, with methods to convert sequences to clonal antibodies
- Grants
- $225K
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 3 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A high throughput next generation sequencing (NGS) pipeline to generate high quality recombinant therapeutic antibodies | $225,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2760 | ORGANIX, INC. | — | — |
| 2761 | KOLIBER BIOSCIENCES INC. | — | — |
| 2762 | VIRTUS THERAPEUTICS CORPORATION | — | — |
| 2763 | SPECIFICA, INC. | — | — |
| 2764 | SAFI BIOTHERAPEUTICS INC | — | — |
| 2765 | NANOVALENT PHARMACEUTICALS INC | — | — |
| 2766 | Florey Biosciences, Inc. | — | $1.4M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Antibody Libraries With Maximized Antibody Developability Characteristicsgranted
- Antibody Libraries With Maximized Antibody Developability Characteristicsgranted
- Antibody Libraries With Maximized Antibody Developability Characteristicsgranted
- Antibody Libraries With Maximized Antibody Developability Characteristicsapplication
- Antibody Libraries With Maximized Antibody Developability Characteristicsapplication
- Single Domain Antibody Libraries With Maximized Antibody Developability Characteristicsapplication
- Phage Display Antibody Libraries Constructed To Maximize Antibody Developability Characteristicsapplication
- Single Domain Antibody Libraries With Maximized Antibody Developability Characteristicsapplication
- Antibody Affinity Maturation Using Natural Liability-free Cdrsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.